Regulation And Legal
Cipla's US Subsidiary Receives One USFDA Form 483 Observation
Cipla discloses a routine USFDA cGMP inspection at its wholly-owned subsidiary InvaGen's New York facility from July 13-17, 2026.
The inspection concluded with the issuance of one Form 483 observation
